Vanda Pharmaceuticals (VNDA) Operating Expenses (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Operating Expenses of $101.9 million for Q1 2026, up 4.48% sequentially from $97.6 million in Q4 2025, and up 11.94% YoY from $91.1 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Operating Expenses (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $101.9 million in Q1 2026.
- Quarterly Operating Expenses rose 11.94% year-over-year to $101.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $378.1 million (up 38.11% YoY) and the FY2025 annual result came in at $367.3 million, up 53.39% from the prior year.
- Operating Expenses advanced to $101.9 million in Q1 2026 per VNDA's latest filing, from $97.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $101.9 million in Q1 2026 and troughed at $44.8 million in Q3 2023.
- A 5-year average of $68.4 million and a median of $60.9 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses decreased 27.03% in 2023, then soared 60.62% in 2025.
- Over 5 years, Operating Expenses stood at $57.9 million in 2022, then dropped by 9.49% to $52.4 million in 2023, then increased by 21.2% to $63.5 million in 2024, then jumped by 53.74% to $97.6 million in 2025, then grew by 4.48% to $101.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $101.9 million, $97.6 million, and $87.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 114.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.34 Mn |
| Mar 31, 2026 | 101.94 Mn |
| Dec 31, 2025 | 97.57 Mn |
| Sep 30, 2025 | 87.54 Mn |
| Jun 30, 2025 | 91.09 Mn |
| Mar 31, 2025 | 91.07 Mn |
| Dec 31, 2024 | 63.46 Mn |
| Sep 30, 2024 | 58.65 Mn |
| Jun 30, 2024 | 60.62 Mn |
| Mar 31, 2024 | 56.70 Mn |
| Dec 31, 2023 | 52.37 Mn |
| Sep 30, 2023 | 44.81 Mn |
| Jun 30, 2023 | 48.92 Mn |
| Mar 31, 2023 | 60.49 Mn |
| Dec 31, 2022 | 57.85 Mn |
| Sep 30, 2022 | 61.41 Mn |
| Jun 30, 2022 | 60.93 Mn |
| Mar 31, 2022 | 67.86 Mn |
| Dec 31, 2021 | 59.38 Mn |
| Sep 30, 2021 | 59.28 Mn |